Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Pacira to Report 2020 Financial Results on Thursday February 25, 2021
07:30am, Thursday, 18'th Feb 2021
PARSIPPANY, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2020 financial results bef
Cisco, Lyft, Uber, VMware and More Thursday Afternoon Analyst Calls
12:29pm, Thursday, 11'th Feb 2021
With the trading day more than halfway over, the broad markets were trading sideways on Thursday.
Pacira BioSciences Announces Equity Investment in GeneQuine Biotherapeutics
08:00am, Tuesday, 26'th Jan 2021
Supports Development of Promising Gene Therapy Platform for Osteoarthritis Supports Development of Promising Gene Therapy Platform for Osteoarthritis
AMRX or PCRX: Which Is the Better Value Stock Right Now?
12:47pm, Friday, 15'th Jan 2021
AMRX vs. PCRX: Which Stock Is the Better Value Option?
Pacira BioSciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
07:30am, Wednesday, 06'th Jan 2021
PARSIPPANY, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference at 7:30 AM ET on
Pacira BioSciences Reports Preliminary Net Product Sales of $38.9 Million for November 2020
07:30am, Wednesday, 09'th Dec 2020
-- EXPAREL average daily sales at 103% of the prior year for the month of November 2020 -- PARSIPPANY, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading prov
--Approval based on four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery-- --EXPAREL is the first long-acting non-opioid option for field block and brachial plexus
Pacira BioSciences Reports Preliminary Net Product Sales of $41.7 Million for October 2020
08:00am, Wednesday, 11'th Nov 2020
-- EXPAREL average daily sales at 112% of the prior year for the month of October 2020 -- -- EXPAREL average daily sales at 112% of the prior year for the month of October 2020 --
Pacira BioSciences to Present at the 2020 Jefferies Virtual London Healthcare Conference
07:30am, Tuesday, 10'th Nov 2020
PARSIPPANY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Jefferies Virtual London Healthcare Conference at 2:05 PM
Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q3 2020 Results - Earnings Call Transcript
03:46pm, Thursday, 29'th Oct 2020
Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q3 2020 Results - Earnings Call Transcript
Pacira (PCRX) Beats Q3 Earnings and Revenue Estimates
09:15am, Thursday, 29'th Oct 2020
Pacira (PCRX) delivered earnings and revenue surprises of 3.03% and 1.90%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Pacira BioSciences Reports Third Quarter 2020 Financial Results and Business Update
08:00am, Thursday, 29'th Oct 2020
-- EXPAREL average daily sales at 110% of the prior year for the third quarter-- -- Conference call today at 8:30 a.m. ET --
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
Tracking John Paulson's Paulson & Company Portfolio - Q2 2020 Update
09:49am, Wednesday, 19'th Aug 2020
John Paulson’s 13F portfolio value increased from $2.62B to $3.13B this quarter. Paulson & Company's largest three positions are Bausch Health, Horizon Therapeutics, and SPDR Gold ETF.
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
12:00am, Wednesday, 19'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
